18th May 2015 08:12
LONDON (Alliance News) - Clinigen Group PLC on Monday said it has entered into an international global access agreement with Dutch pharmaceuticals company Pharming Group NV for HAEi, the C-1 inhibitor deficiencies patient group, for access to Pharming's Ruconest treatment.
Under the agreement, the HAEi GAP access programme will provide eligible patients with hereditary angiodema access to Ruconest in places where they do not currently have access to effective medication to treat acute attacks of the disease. Hereditary angiodema is a rare genetic disorder characterised by spontaneous and recurrent episodes of swelling or the skin in different parts of the body.
"HAEi's ground-breaking program will ensure that HAE sufferers worldwide can gain access to effective and potentially life-saving treatment," said Clinigen's Simon Estcourt, the managing director of the company's managed access programmes.
"Our secure supply chain and regulatory expertise will enable us to work closely with Pharming to supply patients with Ruconest ethically and legitimately, removing the need and the risk for patients to resort to other less reliable or even illegal sources of the drug," Estcourt added.
Shares in Clinigen were up 0.5% to 639.50 pence on Monday.
By Sam Unsted; [email protected]; @SamUAtAlliance
Copyright 2015 Alliance News Limited. All Rights Reserved.
Related Shares:
CLIN.L